
UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …

